共 40 条
[1]
Coluccio C(2017)Hepatitis B in patients with hematological diseases: an update World J Hepatol 9 1043-1053
[2]
Begini P(2009)Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab J Clin Oncol 27 605-611
[3]
Marzano A(2011)Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis Ann Hematol 90 1219-1223
[4]
Pellicelli A(2015)American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy Gastroenterology 148 215-219
[5]
Imperatrice B(2001)Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study Gastroenterology 100 182-188
[6]
Anania G(2013)Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response Arthritis Rheum 65 2783-2790
[7]
Delle Fave G(2017)EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection J Hepatol 67 370-398
[8]
Marignani M(2016)Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders Expert Opin Biol Ther 16 917-926
[9]
Yeo W(2011)Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy J Viral Hepat 18 877-883
[10]
Chan TC(2014)Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial JAMA 312 2521-2530